抗PD-1/PD-L1治疗恶性黑色素瘤的免疫相关不良反应的研究进展

免疫治疗的发展使恶性黑色素瘤的患者总体存活率显著改善，特别是免疫检查点抑制剂(immune checkpoint inhibitor, ICIs)的出现推动了黑色素瘤免疫治疗的发展。ICIs主要针对细胞程序性死亡受体-1(programmed cell death receptor-1,PD-1)、程序性死亡配体-1(programmed death-ligand 1,PD-L1)以及细胞毒性T淋巴细胞相关蛋白-4(cytotoxic T-lymphocyte antigen-4,CTLA-4)。随着ICIs在临床上的大规模应用，越来越多的不良反应也逐渐显现，本篇主要概述PD-1单抗或PD-L1单抗在治疗中出现的不良反应类型及特点。

Research progress on immune related adverse reactions of anti-PD-1/PD-L1 in the treatment of malignant melanoma

The development of immunotherapy has significantly improved the overall survival rate of patients with malignant melanoma.In particular,the emergence of immune checkpoint inhibitors(ICIs) has promoted the development of immunotherapy for melanoma.Currently,the targets of ICIs are programmed cell death receptor-1(PD-1),programmed cell death-ligand 1(PD-L1),and cytotoxic T-lymphocyte antigen-4(CTLA-4).With the large-scale application of ICIs in clinical practice,more and more adverse reactions have gradually emerged.This article mainly summarizes the types and characteristics of adverse reactions in the treatment of PD-1 antibodies or PD-L1 antibodies.